menu
    • menu
    [{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Neu-P11","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Neu-P11","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piromelatine","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurim Pharmaceuticals \/ Syneos Health","highestDevelopmentStatusID":"9","companyTruncated":"Neurim Pharmaceuticals \/ Syneos Health"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Piromelatine","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Kuhnil Pharmaceutical, Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SOUTH KOREA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"KI1001","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Neurim Pharmaceuticals \/ Neurim Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Neurim Pharmaceuticals \/ Neurim Pharmaceuticals"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Kuhnil Pharmaceutical, Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"KI1001","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Neurim Pharmaceuticals \/ Neurim Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Neurim Pharmaceuticals \/ Neurim Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Neurim Pharmaceuticals

    Menu

    Neurim Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Health Canada Approves Slenyto, Extended-Release Melatonin Formulation

                            Details : Slenyto is a child appropriate Extended-release oral minitablet (only 3mm diameter), containing melatonin, a naturally occurring hormone that regulates the sleep-wake cycle.

                            Product Name : Slenyto

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 10, 2025

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neurim Wins EU Approval for Pediatric Melatonin (Slenyto) in ADHD

                            Details : Slenyto is a prolonged-release formulation of melatonin, which is indicated for the treatment of insomnia in children with attention deficit hyperactivity disorder (ADHD).

                            Product Name : Slenyto

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 26, 2025

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neurim Receives Positive CHMP Opinion for Slenyto® in Children with Neurogenic Insomnia

                            Details : Slenyto (melatonin) is an approved melatonin receptor agonist, which is currently being evaluated for the treatment of insomnia in children with neurogenetic disorders.

                            Product Name : Slenyto

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 30, 2024

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piromelatine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

                            Details : Piromelatine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 04, 2022

                            Lead Product(s) : Piromelatine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Slenyto for Insomnia in Children With ASD

                            Details : Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Autism Spectrum Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 18, 2020

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piromelatine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

                            Details : Piromelatine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 25, 2015

                            Lead Product(s) : Piromelatine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KI1001

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Recipient : Kuhnil Pharmaceutical, Co. Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients

                            Details : KI1001 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 14, 2014

                            Lead Product(s) : KI1001

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Recipient : Kuhnil Pharmaceutical, Co. Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment D...

                            Details : Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sleep Wake Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 24, 2013

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Dis...

                            Details : Circadin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dyssomnias.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 19, 2013

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurim Pharmaceuticals

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neu-P11

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

                            Details : Neu-P11 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 12, 2011

                            Lead Product(s) : Neu-P11

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth